Petros Pharmaceuticals, Inc.
PTPI- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001815903
No open-market purchases or sales by Petros Pharmaceuticals, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Petros Pharmaceuticals, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- +1 vs. Q2 2024
- Shares held
- 165.9K
- −24.2K (−12.7%) vs. Q2 2024
- Total value
- $59.2K
- −$27.6K (−31.8%) vs. Q2 2024
- New holders
- 3
- 2 more added
- Sold out
- 2
- 2 more reduced
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PTPI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 15 | $77.6K |
| Q4 2024 | 9 | $38.5K |
| Q3 2024 | 11 | $59.2K |
| Q2 2024 | 12 | $94.9K |
| Q1 2024 | 13 | $94.9K |
| Q4 2023 | 16 | $164.7K |
| Q3 2023 | 14 | $170.6K |
| Q2 2023 | 14 | $214.3K |
| Q1 2023 | 9 | $42.7K |
| Q4 2022 | 10 | $90.6K |
| Q3 2022 | 13 | $355.0K |
| Q2 2022 | 16 | $558.0K |
| Q1 2022 | 19 | $1.30M |
| Q4 2021 | 21 | $3.58M |
| Q3 2021 | 19 | $1.82M |
| Q2 2021 | 22 | $3.02M |
| Q1 2021 | 20 | $4.23M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Petros Pharmaceuticals, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 44,221 | $15.8K | 0.00% | +44,221 | New |
| Geode Capital Management, LLC | 37,517 | $13.4K | 0.00% | +7,147+23.5% | Added |
| Two Sigma Securities, LLC | 32,284 | $11.5K | 0.00% | −21,592−40.1% | Reduced |
| Vanguard Group Inc | 31,811 | $11.4K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 16,128 | $5.76K | 0.00% | +16,128 | New |
| Tower Research Capital LLC (TRC) | 3,255 | $1.16K | 0.00% | −19−0.6% | Reduced |
| National Bank of Canada | 313 | $112 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 200 | $72 | 0.00% | +200 | New |
| Group One Trading, L.P. | 79 | $28 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 72 | $26 | 0.00% | +18+33.3% | Added |
| Morgan Stanley | 19 | $7 | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 0 | $0 | 0.00% | −70,256−100.0% | Sold out |
| 1832 Asset Management L.P. | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |
| Emfo, LLC | – | – | – | – | Not filed |